TD Cowen Initiates on MapLight (MPLT); Says It's Undervalued on Schizophrenia Alone [Yahoo! Finance]
MapLight Therapeutics, Inc. (MPLT)
Company Research
Source: Yahoo! Finance
coverage on MapLight Therapeutics, Inc. (NASDAQ:MPLT) with a Buy rating. The analyst cited the company's pipeline of treatments targeting the central nervous system, or CNS, and neuropsychiatric conditions. TD Cowen Initiates on MapLight (MPLT); Says It's Undervalued on Schizophrenia Alone Thome's bullish thesis is built around ML-007C-MA, which is MapLight's lead drug candidate designed to improve on the profile of Cobenfy. Cobenfy is a Bristol Myers Squibb (NYSE:BMY) product used for adults with schizophrenia. ML-007C-MA is a Cobenfy competitor and MapLight intends it to work just like the latter but with improved convenience. MapLight's drug targets the same M1/M4 receptor mechanism as Cobenfy but with better tolerability, safety, or dosing frequency, according to the company. The company initiated the drug's Phase 2 trial on September 17, 2025, and expects the data to be out in Q3 2026. MapLight is also running a Phase 2 study of ML-007C-MA in Alzheimer's psychosis, an indic
Show less
Read more
Impact Snapshot
Event Time:
MPLT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MPLT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MPLT alerts
High impacting MapLight Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MPLT
News
- Maplight Therapeutics (MPLT) is now covered by Needham & Company LLC. They set a "buy" rating and a $37.00 price target on the stock.MarketBeat
- Maplight Therapeutics (MPLT) is now covered by TD Cowen. They set a "buy" rating on the stock.MarketBeat
- MapLight Therapeutics, Inc. GAAP EPS of -$2.47 [Seeking Alpha]Seeking Alpha
- MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswire
- Maplight Therapeutics (MPLT) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=MPLT&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "MarketBeat
MPLT
Sec Filings
- 4/17/26 - Form 4
- 4/17/26 - Form 4
- 4/17/26 - Form 4
- MPLT's page on the SEC website